Absolutely. And as Ive mentioned, the longer we go in this trial, the better off we are in the long run. It's been a slow going and at times challenging trial to follow from an investor's standpoint, no doubt.
However, given the magnitude of announcing that finally, FINALLY someone has cracked the decades old P53 code and found a way to activate the guardian angel gene safely in humans....well, as much as we want more info and data sometimes, I understand why from DF's standpoint they are mostly keeping a tight lid on things the majority of the time. They need to make darn sure all the Ts are crossed, and Is are dotted before they confidently proclaim they have finally confirmed an oncological breakthrough decades in the making.
I can only imagine how Roche will feel about this, as they put so much effort into nutlins, only to have Kevetrin blow right past them. :-)
Market Data 
Markets 
AI
